PSMA PET-CT Scan

PROCEDURE3 trials

Sponsors

University of Washington, Jonsson Comprehensive Cancer Center, Mayo Clinic

Conditions

Adenocarcinoma of the ProstateAdvanced Prostate AdenocarcinomaAdvanced Prostate CancerCastration-Sensitive Prostate CancerLocalized Prostate CarcinomaMetastatic Castration-Resistant Prostate CarcinomaMetastatic Hormone-sensitive Prostate Cancer (mHSPC)Metastatic Prostate Adenocarcinoma

Phase 2

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

RecruitingNCT06526299

University of WashingtonMetastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2025-04-29End: 2027-12-31Target: 51Updated: 2026-07-07

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

RecruitingNCT07150715

Jonsson Comprehensive Cancer CenterOligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma

Start: 2025-12-12End: 2031-10-31Target: 107Updated: 2025-12-17

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

Not yet recruitingNCT07650240

Mayo ClinicAdenocarcinoma of the Prostate, Advanced Prostate Adenocarcinoma, Advanced Prostate Cancer +9

Start: 2026-07-01End: 2030-12-30Target: 202Updated: 2026-06-17

Related Papers

Alpha-emitting radionuclide or beta-emitting radionuclide combined with metastasis-directed stereotactic body radiotherapy for oligorecurrent prostate adenocarcinoma (ANDROMEDA): A phase II trial.

Journal of Clinical Oncology2026-05-28